New Research Demonstrates 2.3 Point Reduction In HbA1c For Dario Digital Health Users With Baseline HbA1c Greater Than 9 points
Portfolio Pulse from Happy Mohamed
DarioHealth Corp. (NASDAQ:DRIO) announced research presented at the American Diabetes Association 83rd Scientific Sessions, showing significant reductions in HbA1c for Dario users compared to non-users. The study was conducted by Sanofi U.S. under its strategic agreement with Dario.
June 26, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
DarioHealth's research, conducted by Sanofi U.S., shows significant HbA1c reductions for Dario users compared to non-users, potentially increasing demand for Dario's digital health solutions.
The research presented at the American Diabetes Association 83rd Scientific Sessions demonstrates that Dario users experience significant reductions in HbA1c compared to non-users. This positive result may lead to increased demand for Dario's digital health solutions, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100